Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Oral Aleniglipron Reduced Weight at 36 Weeks
In a phase 2b trial, the highest dose produced an estimated 12% mean weight reduction vs 1% with placebo, although gastrointestinal adverse events were common.
Clinical Report: Oral Aleniglipron Reduced Weight at 36 Weeks
Overview
Aleniglipron, an oral GLP-1 receptor agonist, demonstrated significant weight loss in adults with obesity or overweight, achieving reductions of 9% to 12% at 36 weeks compared to 1% with placebo. The study also noted favorable changes in hemoglobin A1c and blood pressure, though gastrointestinal adverse events were common.
Background
The rising prevalence of obesity is associated with increased mortality and healthcare costs. GLP-1 receptor agonists have been approved for weight management and type 2 diabetes treatment.
Data Highlights
Group
Weight Loss at 36 Weeks
Placebo Adjusted Weight Loss
45 mg
9%
8%
90 mg
11%
10%
120 mg
12%
11%
Placebo
1%
N/A
Key Findings
Aleniglipron reduced body weight by 9% to 12% at 36 weeks in a phase 2b trial.
86% of patients on 120 mg achieved at least 5% weight loss compared to 23% on placebo.
Hemoglobin A1c declined by 0.27 to 0.36 percentage points in aleniglipron groups.
Gastrointestinal adverse events occurred in 79% to 89% of aleniglipron-treated patients.
Serious adverse events were reported in 2% to 6% of patients across treatment groups.
Clinical Implications
Clinicians should consider aleniglipron as a potential treatment option for adults with obesity or overweight, particularly those with weight-related comorbidities. Monitoring for gastrointestinal adverse events is essential during treatment.
Conclusion
Aleniglipron reduced body weight by 9% to 12% at 36 weeks in a phase 2b trial, with gastrointestinal side effects reported.
A systematic review and meta-analysis found small, consistent reductions in craving across substance use disorders, while evidence for withdrawal symptoms and substance dependence remained limited.
Surveys captured nearly 7 times as many menopause observations as structured clinical records, with high agreement when both sources identified menopause.
Patients with lower nonischemic resting full-cycle ratio values had more repeat revascularizations despite similar 2-year major cardiovascular event rates.
